The University of Pennsylvania’s Gene Therapy Program partners with the Foundation for Angelman Syndrome Therapeutics to advance gene therapy candidate for Angelman Syndrome

The Foundation for Angelman Syndrome Therapeutics (FAST), a non-profit organization, has entered into an exclusive global collaborative research and development agreement with the University of Pennsylvania to develop an investigational adeno-associated virus (AAV) gene therapy for Angelman syndrome.